Search results for "Rape"

showing 10 items of 2178 documents

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

2021

Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that cover endeavors from screening and engineering viruses as oncolytic cancer therapeutics to their cli…

0301 basic medicinemedicine.medical_treatmentGenetic enhancementvirus targetingMedizinReviewcombination therapychemistry.chemical_compoundDDC 570 / Life sciencesClinical trials0302 clinical medicineKlinisches ExperimentGermanyNeoplasmsMedicineimmunotherapy ; therapeutic transgene ; combination therapy ; Virustherapie ; clinical trials ; virus engineering ; oncolytic virus ; research in Germany ; virus targeting ; virotherapyOncolytic VirotherapyClinical Trials as Topicvirus engineeringKombinationstherapieQR1-5023. Good healthOncolytic VirusesInfectious Diseases030220 oncology & carcinogenesisImmunotherapyvirotherapyGenetic Engineeringresearch in GermanyMicrobiologyVirusViral vector03 medical and health sciencesImmune systemddc:570VirologyAnimalsHumanstherapeutic transgeneVirotherapyoncolytic virusbusiness.industryImmunotherapyVirologyOncolytic virusImmuntherapie030104 developmental biologychemistryVacciniabusinessViruses
researchProduct

Phytochemicals Approach for Developing Cancer Immunotherapeutics

2017

Phytochemicals or their derived compounds are being increasingly recognized as potentially potent complementary treatments for cancer. Among them, some phytochemicals are being actively evaluated for use as adjuvants in anticancer therapies. For instance, shikonin and hypericin were found to induce immunogenic cell death (ICD) of specific cancer cells, and this effect was able to further activate the recognition activity of tumor cells by the host immune system. On the other hand, some derivatives of phytochemicals, such as dihydrobenzofuran lignan (Q2-3) have been found to induce the secretion of an endogenous anticancer factor, namely IL-25, from non-malignant cells. These findings sugges…

0301 basic medicinemedicine.medical_treatmentMini ReviewPharmacologyBiology03 medical and health sciences0302 clinical medicineImmune systemherbal extractCancer immunotherapymedicineCytotoxic T celltumor microenvironmentPharmacology (medical)PharmacologyTumor microenvironmentcancer immunotherapylcsh:RM1-950Cancermedicine.diseasephytochemicalslcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCancer cellImmunogenic cell deathCancer vaccineFrontiers in Pharmacology
researchProduct

Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases. A Consensus Document by the Italian Society …

2021

Hypertension is a major contributor to fatal/nonfatal cardiovascular diseases, and timely identification and appropriate management of factors affecting hypertension and its control are mandatory public health issues. By inducing neurohormonal alterations and metabolic impairment, sleep disorders have an impact on a variety of cardiovascular risk factors, including hypertension, and ultimately increase the risk of cardiovascular events. There is evidence that qualitative and quantitative sleep disorders are associated with resistant hypertension and with impaired circadian blood pressure variations. However, sleep disturbances are often unrecognized, or heterogeneity exists in their managem…

0301 basic medicinemedicine.medical_treatmentSleep disorders.Comorbidity0302 clinical medicineCardiovascular DiseaseSleep Initiation and Maintenance DisordersInsomniaContinuous positive airway pressureSleep Apnea ObstructiveContinuous Positive Airway Pressureblood pressureHeart Disease Risk FactorPrognosisSleep in non-human animalsCircadian RhythmAntihypertensive AgentCardiovascular Diseasessleep disordersmedicine.symptomCardiology and Cardiovascular MedicineRisk assessmentHumancardiovascular riskmedicine.medical_specialtyConsensusSleep ApneahypertensionPrognosiConsensuRisk Assessment03 medical and health sciencesTherapeutic approachInternal MedicinemedicineHumansHealthy LifestyleIntensive care medicineConsensus DocumentAntihypertensive AgentsBlood pressure; Cardiovascular risk; Hypertension; Sleep disorders; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Comorbidity; Consensus; Healthy Lifestyle; Heart Disease Risk Factors; Humans; Hypertension; Prognosis; Risk Assessment; Risk Reduction Behavior; Sleep Apnea Obstructive; Sleep Initiation and Maintenance Disorders; Continuous Positive Airway Pressure; SleepSleep disorderbusiness.industryObstructivePublic healthmedicine.diseaseComorbidity030104 developmental biologyBlood pressureHeart Disease Risk Factorsblood pressure; cardiovascular risk; hypertension; sleep disordersbusinessSleepRisk Reduction Behavior030217 neurology & neurosurgery
researchProduct

Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages

2020

free open access article 31 p.; International audience; In this work, we have explored natural unmodified low- and high-density lipoproteins (LDL and HDL) as selective delivery vectors in colorectal cancer therapy. We show in vitro in cultured cells and in vivo (NanoSPECT/CT) in the CT-26 mice colorectal cancer model that LDLs are mainly taken up by cancer cells, while HDLs are preferentially taken up by macrophages. We loaded LDLs with cisplatin and HDLs with the heat shock protein-70 inhibitor AC1LINNC, turning them into a pair of “Trojan horses” delivering drugs selectively to their target cells as demonstrated in vitro in human colorectal cancer cells and macrophages, and in vivo. Coupl…

0301 basic medicinemedicine.medical_treatmentcisplatinlcsh:Medicineheat shock protein inhibitorCancer immunotherapy[CHIM.THER]Chemical Sciences/Medicinal ChemistrySpectrum Analysis RamanMiceDrug Delivery Systems0302 clinical medicineCancer immunotherapyChemistryRselective cell targetingGeneral Medicine3. Good healthLipoproteins LDLOncology030220 oncology & carcinogenesisMedicinecancer therapylipids (amino acids peptides and proteins)Colorectal NeoplasmsLipoproteins HDLResearch Articlemedicine.drug[CHIM.THER] Chemical Sciences/Medicinal ChemistryLipoproteinsTherapeuticsCell Line03 medical and health sciencesImmune systemIn vivoCell Line TumormedicinevectorizationAnimalsHumansCisplatinMacrophageslcsh:RCancermedicine.diseaseColorectal cancerIn vitro030104 developmental biologyCancer cellCancer researchNanocarriers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy

2020

Myotonic dystrophy type 1 (DM1) is a chronically debilitating, rare genetic disease that originates from an expansion of a noncoding CTG repeat in the dystrophia myotonica protein kinase (DMPK) gene. The expansion becomes pathogenic when DMPK transcripts contain 50 or more repetitions due to the sequestration of the muscleblind-like (MBNL) family of proteins. Depletion of MBNLs causes alterations in splicing patterns in transcripts that contribute to clinical symptoms such as myotonia and muscle weakness and wasting. We previously found that microRNA (miR)-23b directly regulates MBNL1 in DM1 myoblasts and mice and that antisense technology (“antagomiRs”) blocking this microRNA (miRNA) boost…

0301 basic medicinemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesMyotonic dystrophyArticleantagomiR03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoverymicroRNAMedicineMBNL1AntagomirProtein kinase AmiRNAmyotonic dystrophybusiness.industrylcsh:RM1-950Muscle weaknessmedicine.diseaseMyotoniaMbnl1030104 developmental biologylcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesisRNA splicingCancer researchHSALR miceMolecular Medicinemedicine.symptomDM1antisense oligonucleotidesbusinessMolecular Therapy: Nucleic Acids
researchProduct

Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher d…

2018

Anca Zimmermann,1 Radu A Popp,2 Heidi Rossmann,3 Simona Bucerzan,4 Ioana Nascu,4 Daniel Leucuta,5 Matthias M Weber,1 Paula Grigorescu-Sido41Department of Endocrinology and Metabolic Diseases, 1st Clinic and Polyclinic of Internal Medicine, University of Mainz, Mainz, Germany; 2Department of Medical Genetics, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 3Institute for Clinical Chemistry and Laboratory Medicine, University of Mainz, Mainz, Germany; 4Center of Genetic Diseases, 1st Pediatric Clinic, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 5Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy, Cluj-Napoca, RomaniaPurpose: Oste…

0301 basic medicinemusculoskeletal diseasesmedicine.medical_specialtyTherapeutics and Clinical Risk ManagementOsteoporosisGaucher diseasegene variantsCalcitriol receptorBone remodeling03 medical and health sciencesOsteoprotegerinInternal medicineGenotypecalcitonin receptormedicinevitamin D receptorPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsCalcitonin receptorOriginal ResearchChemical Health and Safetybiologybusiness.industryGeneral Medicinemedicine.diseaseosteoporosis030104 developmental biologyEndocrinologyosteoprotegerinOsteocalcinbiology.proteinbusinessSafety ResearchEstrogen receptor alphaTherapeutics and Clinical Risk Management
researchProduct

Initiation of Vancomycin Therapy and the First Therapeutic Drug Monitoring

2021

Abstract There have been a limited number of studies in Latvia that were focused on vancomycin therapeutic drug monitoring (TDM), especially during the initiation phase of the therapy. The aim of this study was to investigate details of vancomycin therapy in its initiation phase and to analyse the results of the first therapeutic drug monitoring within a multidisciplinary hospital in Latvia. A retrospective observational study was performed in a multidisciplinary hospital in Latvia. Adult patients hospitalised in an intensive care unit and undergoing vancomycin therapy with at least one concentration measurement were included in this study. Data about patients included demographic and clini…

0301 basic medicinenarrow therapeutic rangeMultidisciplinaryGeneral interestmedicine.diagnostic_testconcentration measurementScience030106 microbiologyQantibacterial agentsPharmacologyminimum inhibitory concentrationVancomycin therapy03 medical and health sciencesMinimum inhibitory concentration0302 clinical medicineTherapeutic drug monitoringmedicine030212 general & internal medicineProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Cardiotoxicity and Cardioprotection by Artesunate in Larval Zebrafish

2019

Although artesunate (ART) is generally accepted as a safe and well-tolerated first-line treatment of severe malaria, cases of severe side effects and toxicity of this compound are also documented. This study applied larval zebrafishes to determine the acute toxicity and efficacy of ART and performed RNA-sequencing analyses to unravel the underlying signaling pathways contributing to ART’s activities. Results from acute toxicity assay showed that a single-dose intravenous injection of ART from 3.6 ng/fish (1/9 maximum nonlethal concentration) to 41.8 ng/fish (lethal dose 10%) obviously induced pericardial edema, circulation defects, yolk sac absorption delay, renal edema, and swim bladder l…

0301 basic medicinenatural productsHealth Toxicology and MutagenesisShort ReportmalariaDevelopmental toxicityPharmacologyToxicologyNephrotoxicity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEdemamedicinecancernetwork pharmacologyCardiotoxicityChemical Health and Safetybusiness.industrylcsh:RM1-950Public Health Environmental and Occupational Healthmedicine.diseaseAcute toxicity030104 developmental biologylcsh:Therapeutics. PharmacologychemistryArtesunate030220 oncology & carcinogenesisHeart failureToxicitymedicine.symptombusinessDose-Response
researchProduct

Corrigendum: Seabuckthorn Pulp Oil Protects against Myocardial Ischemia–Reperfusion Injury in Rats through Activation of Akt/eNOS

2016

Seabuckthorn (SBT) pulp oil obtained from the fruits of seabuckthorn [Hippophae rhamnoides L. (Elaeagnaceae)] has been used traditionally for its medicinal and nutritional properties. However, its role in ischemia–reperfusion (IR) injury of myocardium in rats has not been elucidated so far. The present study reports the cardioprotective effect of SBT pulp oil in IR-induced model of myocardial infarction in rats and underlying mechanism mediating activation of Akt/eNOS signaling pathway. Male albino Wistar rats were orally administered SBT pulp oil (5, 10, and 20 ml/kg/day) or saline for 30 days. On the day 31, ischemia was induced by one-stage ligation of left anterior descending coronary a…

0301 basic medicinenatural productsIschemia030204 cardiovascular system & hematologyPharmacologyseabuckthornmedicine.disease_causeLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnosLactate dehydrogenaseMedicineoxidative stressPharmacology (medical)Original ResearchPharmacologylehberrybiologybusiness.industrylcsh:RM1-950apoptosisCorrectionbiology.organism_classificationmedicine.diseaseMalondialdehydemyocardial ischemia–reperfusion injury030104 developmental biologylcsh:Therapeutics. PharmacologyBiochemistrychemistryinflammationedible oilPulp (tooth)businessReperfusion injuryOxidative stressFrontiers in Pharmacology
researchProduct

A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer

2017

Crosstalk between the androgen receptor (AR) and other signaling pathways in prostate cancer (PCa) severely affects the therapeutic outcome of hormonal therapy. Although anti-androgen therapy prolongs overall survival in PCa patients, resistance rapidly develops and is often associated with increased AR expression and upregulation of the HER2/3-AKT signaling pathway. However, single agent therapy targeting AR, HER2/3 or AKT usually fails due to the reciprocal feedback loop. Previously, we reported that wedelolactone, apigenin, and luteolin are the active compounds in Wedelia chinensis herbal extract, and act synergistically to inhibit the AR activity in PCa. Here, we further demonstrated th…

0301 basic medicinenatural productsmedicine.drug_classPharmacologyurologic and male genital diseasesAntiandrogen03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineHER3HER2LNCaPMedicineEnzalutamidePharmacology (medical)Pharmacologybusiness.industrylcsh:RM1-950apoptosisprostate cancerWedelolactonemedicine.diseaseAndrogenanimal modelsAndrogen receptorlcsh:Therapeutics. Pharmacology030104 developmental biologychemistry030220 oncology & carcinogenesisHormonal therapybusinessFrontiers in Pharmacology
researchProduct